Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
great find, Wait!
What does that mean? Grab more... Wish you had another 10K layin' around?
What about ADXS and MDGN?
And with all of this innovation, the PPSb continues to decline. Unbelievable. Can this be the work
of shorts???
Why does it have to be a wager? If you know there has been further dilution, show it.
Arcam is in Wikipedia for EBM:
http://en.wikipedia.org/wiki/Electron_beam_melting
Is this old news:
Company checkpoints
By Stephen Parmley, Senior Writer
Published on Thursday, January 29, 2015
The spate of biotechs announcing new targets, combinations or milestones in the PD-1space in the last two months suggests pharmas may not have to wait long to add second-generation therapies to their pipelines of checkpoint inhibitors. While AnaptysBio Inc. and cCAM have preclinical targets that could complement PD-1 inhibition, OncoSec Medical Inc. is about to enter the clinic with a combination that uses PD-1 suppression to potentiate the immune activation of IL-12.
The push for new compounds is driven by the fact that many patients don't respond to PD-1 therapies because their tumors have either low or no expression of the receptor's ligand, PD-L1. By acting through complementary pathways, upregulating the expression of PD-L1 or increasing the ability of antigen-presenting cells to trigger immune pathways, the next generation of compounds is designed to potentiate the tumor-killing effect of PD-1 inhibitors (See Cover Story).
Nice to see you back talking about ONCS.
Thanks for the explanation.
I'm not sure I understand. This is a recent article and yes electroporation has been around since the 1930's; however in this article it states effectiveness:
The effects of this process have been confirmed in countless small trials
What else is needed?
It has been proven to be effective. See article for Feb. 17:
http://wallstcheatsheet.com/business/big-pharma-continues-the-race-for-electroporation.html/?a=viewall
I'm going to rain on your parade.
Arcam has continually surprised to the upside. I own Arcam only to see the price cave from $27 all the way down to $18.50 in a six month window.
There is almost no interest in this stock
AND
Anyone who buys the stock, F for foreign also has to pay a whopping $60 brokerage fee. So don't buy 100 shares. Buy at least 250 and be prepared for the stock price not to move at all.
There must be a lot of people selling. No other reason. Too much time to wait.
Really, and who are all those candidates? Just name a few that have the qualifications and want to
swap places with Dr. Pierce.
Could you elaborate on that statement? Plenty of ONCS posters have stated this but we keep on seeing how it knocked/pounded downward after new releases
Thanks for the help in understanding this situation.
This is incredible news.
"[A] statistically significant difference (p = 0.0054) was observed when comparing overall survival between patients who had a best overall response of at least stable disease or better (median OS = 49.1 months) versus patients who only had disease progression while on study (median OS = 10.9 months)."
Should we just ask cancer patients... Would you like to live another 39 months with this treatment or die tomorrow?
I don't understand how this can be viewed negatively.
"Is this only among those patients with SD or CR during the study ( I recall that about 60% of the patients in the trial had PD. )."
Please explain these abbreviations. Are you an oncologist?
Can I ask you? Did electroporation begin in the 1930's?
Simple definition of milestone:
an action or event marking a significant change or stage in development.
Yes, I think so.
Another milestone:
OncoSec Medical Collaborates with PerkinElmer and University of California, Los Angeles to Evaluate Patient-Selection Biomarker in Immunotherapy
http://finance.yahoo.com/news/oncosec-medical-collaborates-perkinelmer-university-110200388.html
I thought he was serious. Thank you Furbush for pointing that out.
Furbush: You can't be serious about this "was" published. Medical articles are published in this way - appearing ahead of date.
dawson
If you go to TCRT.org it is definitely an article published this coming month: take a look at the graphs - they are posted on this site.
Open Access (Express)
Electroporation
Delivery of Interleukin-15 to B16 Melanoma by Electroporation Leads to Tumor Regression and Long-term Survival (551-560)
Electroporation (EP) is a method used to physically deliver therapeutic molecules such as plasmid DNA directly to tissues. It has been used safely and successfully in clinical studies and preclinical cancer models to deliver genes to a variety of tissues. In cancer research cytokine therapy is emerging as a promising tool that can be used to boost the host response to tumor antigens. The delivery of cytokines as recombinant proteins can result in toxicity and other adverse effects; however the delivery of cytokine genes using EP has been shown to be safe and effective. Interleukin 15 (IL-15) is a cytokine that promotes the innate as well as the adaptive immune response to cancer cells and bacterial pathogens. In this study we used EP to deliver a human IL-15 plasmid (phIL-15) directly to tumors to examine its anti-cancer effects. B16.F10 melanoma tumors were induced in C57BL/6J mice and phIL-15 was delivered three times over the course of a week. Expression of the transgene, tumor volume, long-term survival and resistance to challenge were monitored in these animals. Delivery of IL-15 plasmid by EP resulted in increased IL-15 expression within the tumor compared to the injection only control. This expression peaked at 12 to 18 hours after the first delivery and was sustained at lower levels after the second and third deliveries. The delivery of the phIL-15 resulted in tumor regression, long-term survival and greater protection against tumor recurrence when cancer cells were reintroduced were compared to control plasmid. From these results we can conclude that the delivery of IL-15 plasmid to tumors using EP is a promising avenue to investigate for its anti-tumor effects, however more work needs to be done to increase the stability of the gene once it is delivered and to elucidate the anti-tumor mechanism.
prevnext
marrero-figure-3.gif marrero-figure-4.gif marrero-figure-5.gif marrero-figure-1.gif marrero-figure-2.gif marrero-figure-3.gif marrero-figure-4.gif marrero-figure-5.gif marrero-figure-1.gif marrero-figure-2.gif marrero-figure-3.gif
Citation References PubMed Download Dates
<< Go Back to TCRT December 2014
Well what are you stating? This is a fabrication? What you are referring to was published in 2010:
Curr Gene Ther. 2010 Aug;10(4):312-7.
Electroporation gene therapy preclinical and clinical trials for melanoma.
Heller LC1, Heller R.
Author information
Abstract
In vivo electroporation (EP) is a versatile delivery method for gene transfer which can be applied to any accessible tissue. Delivery of plasmid DNA encoding therapeutic genes or cDNAs with in vivo EP has been tested extensively in preclinical melanoma models. Direct delivery to the tumor has been shown to generate a direct antitumor effect. Delivery to alternative sites may generate additional therapeutic options, for example the production of cancer vaccines, the reduction of tumor angiogenesis, or the induction of tumor cell apoptosis. Several of the preclinical therapies tested have a demonstrated therapeutic effect against melanomas. Two immunotherapies have advanced to melanoma clinical trials. Delivery of a plasmid DNA encoding interleukin-12 (IL-12) or interleukin-2 (IL-2) using electroporation was demonstrated to be a safe with no grade 3 or 4 toxicities reported. Delivery of IL-12 with electroporation resulted in significant necrosis of melanoma cells in the majority of treated tumors and significant lymphocytic infiltrate in biopsies from patients in several cohorts. In addition, clinical evidence of responses in untreated lesions suggested the induction of a systemic response following therapy. This review discusses preclinically tested electroporation gene therapies for melanoma with clinical potential and the conversion of these therapies to clinical trials.
And this one too:
Eur J Cancer. 2014 Oct;50(15):2705-13. doi: 10.1016/j.ejca.2014.07.006. Epub 2014 Jul 28.
A protective effect after clearance of orthotopic rat hepatocellular carcinoma by nanosecond pulsed electric fields.
Chen R1, Sain NM2, Harlow KT2, Chen YJ2, Shires PK3, Heller R2, Beebe SJ4.
Author information
Abstract
Strategies for treating liver cancer using radiation, chemotherapy combinations and tyrosine kinase inhibitors targeting specific mutations have provided longer survival times, yet multiple treatments are often needed and recurrences with new malignant phenotypes are not uncommon. New and innovative treatments are undoubtedly needed to successfully treat liver cancer. Over the last decade, nanosecond pulsed electric fields (nsPEFs) have shown promise in pre-clinical studies; however, these have been limited to treatment of skin cancers or xenographs in mice. In the present report, an orthotopic hepatocellular carcinoma (HCC) model is established in rats using N1-S1 HCC cells. Data demonstrate a response rate of 80-90% when 1000 pulses are delivered with 100ns durations, electric field strengths of 50kV/cm and repetition rates of 1Hz. N1-S1 tumours treated with nsPEFs expressed significant number of cells with active caspase-3 and caspase-9, but not caspase-8, indicating an intrinsic apoptosis mechanism(s) as well as caspase-independent mechanisms. Most remarkably, rats with successfully ablated tumours failed to re-grow tumours when challenged with a second injection of N1-S1 cells when implanted in the same or different liver lobe that harboured the original tumour. Given this protective effect, infiltration of immune cells and the presence of granzyme B expressing cells within days of treatment suggest the possibility of an anti-tumour adaptive immune response. In conclusion, NsPEFs not only eliminate N1-S1 HCC tumours, but also may induce an immuno-protective effect that defends animals against recurrences of the same cancer.
Copyright © 2014 Elsevier Ltd. All rights reserved.
KEYWORDS:
Absence of recurrence; Apoptosis; Cancer ablation; Electroporation; Granzyme B; Hepatocellular carcinoma; Immunity; Nanosecond pulsed electric fields; Non-thermal; Orthotopic model
PMID: 25081978 [PubMed - in process]
Taking Money's lead, I decided to go and search Pub Med - hopefully everyone knows the Pub Med database which is a free resource sponsored by leading medical libraries, CDC and others. I typed in the search field Richard Heller. In 2014, Heller has published with other authors several articles; however this one published in Dec 2014 may interest everyone. Heller is employed by Old Dominion U.
Technol Cancer Res Treat. 2014 Dec;13(6):551-60. doi: 10.7785/tcrtexpress.2013.600252. Epub 2013 Aug 31.
Delivery of Interleukin-15 to B16 Melanoma by Electroporation Leads to Tumor Regression and Long-term Survival.
Marrero B1, Shirley S, Heller R.
Author information
1Department of Molecular Medicine, University of South Florida, Tampa, Florida 33613, USA. rheller@odu.edu.
Abstract
Electroporation (EP) is a method used to physically deliver therapeutic molecules such as plasmid DNA directly to tissues. It has been used safely and successfully in clinical studies and preclinical cancer models to deliver genes to a variety of tissues. In cancer research cytokine therapy is emerging as a promising tool that can be used to boost the host response to tumor antigens. The delivery of cytokines as recombinant proteins can result in toxicity and other adverse effects; however the delivery of cytokine genes using EP has been shown to be safe and effective. Interleukin 15 (IL-15) is a cytokine that promotes the innate as well as the adaptive immune response to cancer cells and bacterial pathogens. In this study we used EP to deliver a human IL-15 plasmid (phIL-15) directly to tumors to examine its anti-cancer effects. B16.F10 melanoma tumors were induced in C57BL/6J mice and phIL-15 was delivered three times over the course of a week. Expression of the transgene, tumor volume, long-term survival and resistance to challenge were monitored in these animals. Delivery of IL-15 plasmid by EP resulted in increased IL-15 expression within the tumor compared to the injection only control. This expression peaked at 12 to 18 hours after the first delivery and was sustained at lower levels after the second and third deliveries. The delivery of the phIL-15 resulted in tumor regression, long-term survival and greater protection against tumor recurrence when cancer cells were reintroduced compared to control plasmid. From these results we can conclude that the delivery of IL-15 plasmid to tumors using EP is a promising avenue to investigate for its anti-tumor effects, however more work needs to be done to increase the stability of the gene once it is delivered and to elucidate the anti-tumor mechanism.
PMID: 24000979 [PubMed - in process] Free full text
Since your last post, SLTD has decreased enormously. Pump all you want but it is not SCTY.
Treating cancer with HIV, a success story. However, I will take electroporation over a disabled HIV
any day.
http://www.newser.com/story/198416/mans-cancer-knocked-out-using-hiv-as-a-tool.html?utm_source=part&utm_medium=earthlink&utm_campaign=rss_topnews
The other problem, of course, is the fees for buying the ADR. As I stated a couple of weeks ago, it is really high. It looks like it could go lower so I'm going to wait to buy more.
This stock has dropped almost $5 in the past month.
Pretty much the full name:
Inversiones Copu SICAV SA
I am just plain waiting until they announce good info. It's coming have no idea when, don't care.
Yes, I agree. The YMB reference was really abbreviated and didn't say much either.
This was announced yesterday on the YMB although greatly shortened.
Last week I bought some shares on Schwab and you're right - the fee is enormous compared to my usual trades with the company. $6.95 for US companies all day long compared to Arcam $58.95!
Thanks for the heads up. This is a foreign transaction, although down from the $100 they charged
abouta year ago.
How about on their freakin' website: top item.
http://sigmalabsinc.com/index.php?page=news
Well stated, Furbush. And along with the profit, we have persons like you and Money and Sal and Ahab, and Twiz, Zoriden, Ero, Wait, Bradrad, Trading.Jeff, Tremors, lasers, Bob, and others who lend vital info to this board.
If I haven't said it lately, THANK YOU.
Dawson
One of the reasons why the administrators gave us a timeout is because we name persons who should be put on ignore. Investors Hub states in their rules that this is not allowed and can lead to suspension. Naming a person and ignore is comparable to bashing.
Just read the rules to figure out what you need to know. Don't put it on this board.
Gemmil: I sent you a private message. Can you read it?